PHARMAP 2026 Reveals How PLC Automation Is Reshaping Pharma Manufacturing
On this page
PHARMAP 2026 Reveals How PLC Automation Is Reshaping Pharma Manufacturing
When senior decision-makers from Astellas Pharma Europe, GSK, ESTEVE, Laboratoires Théa, and Recipharm gathered in Amsterdam on April 20, 21 for the Pharmaceutical Manufacturing and Packaging Congress (PHARMAP 2026), one message resonated across every panel and roundtable: the era of isolated production systems is over, and
Detail
is now the operational backbone of compliant, cost-efficient pharmaceutical manufacturing.
Hosted against a backdrop of geopolitical supply chain disruption and escalating regulatory demands, the 2026 edition of this closed-door congress drew over 300 industry leaders to explore how automation technologies , particularly Programmable Logic Controllers (PLCs) , are redefining global manufacturing strategies, packaging innovation, and quality management in life sciences.
The convergence of Pharma 4.0 mandates and FDA 21 CFR Part 11 compliance requirements means PLCs are no longer just control devices , they are data integrity gatekeepers. PHARMAP 2026 confirmed that manufacturers investing in PLC-driven batch record automation and real-time process control are gaining a decisive competitive edge in both speed-to-market and regulatory readiness.
The pharmaceutical industry faces a paradox: demand for personalized therapies and faster drug approvals is rising, yet manufacturing margins remain under pressure. At PHARMAP 2026, speakers made clear that the solution lies in
Henk Mollee, Head of CMO Management at Astellas Pharma Europe B.V., presented a case study on site divestment and partnership evolution, illustrating how PLC-integrated manufacturing execution systems (MES) enable seamless technology transfer and batch consistency across global contract manufacturing networks.
GSK's recently announced $30 billion investment in U.S. R&D and manufacturing , including $1.2 billion allocated for AI and advanced digital technologies , signals a sector-wide pivot toward fully connected, PLC-enabled "lights-out" production facilities. The pressure is now on mid-tier manufacturers to follow suit or risk supply chain exclusion.
One of the most discussed topics at PHARMAP 2026 was the modernization of batch processing control. Traditional manual data entry and paper-based batch records , still prevalent in legacy pharma plants , are increasingly viewed as unacceptable risk vectors in an era of heightened regulatory scrutiny.
Sourcing help
Send the BOM for one quote covering active stock, EOL stock and cross-references.
Need a quote for this part?
Send us the part number or article link — we will confirm price, availability and lead time.
